Insights
Recent tax and legal developments across the sectors we serve, with a focus on Egypt and the UAE. Briefings prepared by Fouad El-Watan.
Egypt's 2025 Tax Reforms: The Compliance Reset Facing Pharmaceutical Manufacturers and Distributors
Egypt's 2025 tax legislation, from the February facilitation laws to the VAT overhaul under Law No. 157 of 2025, reshapes the compliance burden on pharmaceutical companies even though finished medicines stay VAT-exempt. Expanded e-invoicing, refined recovery rules, and new SME relief all demand a fresh review of the sector's position.
Coding Mandates and a New State Procurement Channel: Egypt's 2025 Regulatory Reset for Pharmaceuticals
Two 2025 instruments redraw the legal map for pharmaceutical companies in Egypt: EDA Decree No. 161 of 2025, which imposes unified coding and traceability, and MoF Circular No. 94 of 2025, which routes public-sector procurement through a tripartite arrangement with the Unified Procurement Authority. Both carry market-access consequences companies cannot treat as optional.
These briefings track the sectors we work in.
Explore the industries we serve